cAMP is a key mediator of GPCR signaling but is inversely regulated by Gαs and Gαi-coupled GPCRs, leading to assay challenges. Cisbio now offers cAMP HTRF assays optimized for your particular GPCR ...

(RTTNews) - Coherus BioSciences, Inc. (CHRS), Monday announced data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in ...

Coherus BioSciences has announced promising results from its ongoing Phase 1 clinical trial of CHS-114, a selective anti-CCR8 antibody, in combination with toripalimab for patients with recurrent ...